Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pharvaris N.V. (NQ: PHVS ) 17.96 -0.54 (-2.92%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 57,297 Open 18.79 Bid (Size) 7.260 (2) Ask (Size) 29.03 (1) Prev. Close 18.50 Today's Range 17.85 - 19.16 52wk Range 15.00 - 33.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium Today 6:50 EDT From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024 August 14, 2024 PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Performance YTD -30.58% -30.58% 1 Month +3.22% +3.22% 3 Month -7.42% -7.42% 6 Month -25.82% -25.82% 1 Year -7.42% -7.42% More News Read More Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update August 14, 2024 From Pharvaris N.V. Via GlobeNewswire Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Via Investor's Business Daily Analyst Expectations for Pharvaris's Future December 07, 2023 Via Benzinga Pharvaris Announces Annual Meeting of Shareholders June 11, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses June 04, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses May 13, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 May 08, 2024 Via InvestorPlace Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 April 10, 2024 Via InvestorPlace Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 10, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer April 10, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference April 04, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses March 18, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses March 06, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 March 05, 2024 From Pharvaris N.V. Via GlobeNewswire Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting February 22, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Extraordinary Meeting of Shareholders February 16, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present at the WSAAI Annual Meeting 2024 January 26, 2024 From Pharvaris N.V. Via GlobeNewswire Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision January 22, 2024 Via Investor's Business Daily Exposures Product Safety FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps January 22, 2024 Via Benzinga Exposures Product Safety Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks January 22, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities January 05, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 December 08, 2023 From Pharvaris N.V. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.